Although mother-to-child transmission (MTCT) rates are at an all-time low in Western Europe, potentially preventable transmissions continue to occur. Duration of antenatal combination antiretroviral therapy (ART) is strongly associated with MTCT risk.
Background
Rates of mother-to-child transmission (MTCT) of HIV-1 have been reduced to around 1% in Western Europe, where women have access to the full combination of measures for prevention of MTCT (PMTCT) [1] [2] [3] [4] , but some transmissions still occur [1, 4] . Voluntary antenatal HIV screening offered to all women is policy in most of these countries [5] , but undiagnosed maternal HIV infection remains a reason for continued transmissions, as does seroconversion in pregnancy, non-suppressive antenatal antiretroviral therapy (ART) and adverse social circumstances in pregnancy, precluding access to optimal antenatal care [4] .
An increasing number of HIV-infected pregnant women are conceiving whilst receiving ART [6, 7] . For those who are not already on treatment at conception, either because they have no clinical or immunological indications for ART or because they are diagnosed with HIV for the first time in pregnancy, antenatal ART is recommended to reduce MTCT risk [8, 9] . Decisions around timing of treatment initiation in these women must balance the possibility of adverse effects (such as preterm delivery or anaemia in the infant) [9] [10] [11] [12] [13] with the clinical needs of the mother and the reduction in MTCT risk associated with longer duration of antenatal ART [1, 2, [14] [15] [16] . Time to undetectable HIV viral load depends on individual baseline viral load, highly active antiretroviral therapy (HAART) regimen and treatment history, drug resistance, coinfections and ethnicity [17, 18] , and virological suppression is not always achieved by delivery [1, 17, 19] . For women requiring ART for PMTCT only, British and United States guidelines recommend individualised decisions around when to start, with a move towards earlier ART initiation whilst allowing for avoidance of ART exposure during the first trimester, the period of greatest potential teratogenic risk [8, 9] . The World Health Organisation (WHO) updated its guidance in 2010, and recommends initiating ART for PMTCT from 14 weeks of gestation to ensure maximum uptake, especially in the second trimester, and to reduce the risk of intrauterine transmission [20] .
Identifying factors associated with missed opportunities for PMTCT is a priority to optimise maternal health and achieve the virtual elimination of MTCT [20] . Given the importance of antenatal ART for PMTCT, we aimed to explore factors associated with receipt of insufficient ART in a Western and Central European cohort.
Methods
The European Collaborative Study (ECS) on HIV-infected pregnant women and their children is an ongoing birth cohort study, in which HIV-1 infected pregnant women are enrolled and their infants prospectively followed according to a standard protocol [21] . Data were collected anonymously on standard questionnaires on maternal socio-demographic and clinical information, delivery and infant characteristics [21] . This analysis was limited to births from January 2000 to July 2009 in nine countries (Belgium, Denmark, Germany, Italy, the Netherlands, Poland, Spain, Sweden and the UK). Multiple births were excluded because of their association with preterm delivery, a factor potentially limiting duration of antenatal ART. Figure 1 summarises the availability of data on receipt and duration of antenatal ART. The main outcome was receipt of 'insufficient antenatal ART', defined as receipt of no ART in pregnancy or short duration of ART, initiated 1-13 days before delivery. This definition was chosen in order to focus on those with the most elevated risk of vertical transmission [22, 23] .
Definitions
Women receiving ART in pregnancy but with missing treatment duration (n=246) were included in the ≥14 days of ART group; 84% (191/228) were diagnosed pre-conception, 33%
(48/144) had undetectable viral load at delivery, and 66% (103/155) had a CD4 count >350 cells/mm 3 at last antenatal measure.
Where HIV diagnosis was recorded one day either side of delivery (n=6), women were categorised as diagnosed intrapartum. Women diagnosed with HIV more than one day postpartum (n=3) were excluded. Gestational age was reported to the nearest completed week based on ultrasound or, in absence of ultrasound, last menstrual period. The first trimester was defined as 1-12 weeks of gestation, the second trimester as 13 to 26 weeks and the third trimester as 27 weeks of gestation onwards [24] . We defined an HIV diagnosis as "late" if it occurred during the third trimester or intrapartum. Delivery before 34 weeks gestation (precluding 14 days of antenatal ART if started at week 32, the latest suggested by British guidelines [9] ) was investigated as a factor associated with receiving no and ethnicity, was used in the models, as this was thought to more closely reflect immigrant status, a factor possibly affecting healthcare access. Model selection followed a forward stepwise approach, with each factor tested for its significant contribution to the model's goodness of fit using the likelihood ratio test (significance level of p≤0.1). Random effects models were fitted in all analyses to account for underlying, unobserved variation in the outcome by country of delivery [26] . All models were adjusted a priori for year of delivery to account for changes in clinical practice over time [21] .
We hypothesized that different factors could be associated with receiving insufficient antenatal ART among women diagnosed with HIV pre-and post-conception [27] , and therefore carried out stratified analyses in these two groups.
Statistical analyses were performed with Stata version 11.0 for Windows (StataCorp LP, College Station, Texas, USA).
Results
A total of 2148 deliveries between January 2000 and July 2009 were reported in 1940 women;
173 women had two pregnancies, 16 had three and one woman had four. Of the 2148 pregnancies, 142 (7%) were in women who received no ART, and a further 41 (2%) were in women who received less than two weeks of ART before delivery ( Figure 1 ). Baseline maternal and pregnancy characteristics by receipt of antenatal ART are given in Table 1 . Overall, in two fifths of mother-child pairs the mother was born in sub-Saharan Africa, three-quarters were married or cohabiting and around a fifth had an IDU history. Median age at delivery was 31. In almost three-quarters of pregnancies the woman was aware of her HIV infection before conception (Table 1) , and in over a third of these (39%, 479/1229) the woman conceived 
Factors associated with receiving insufficient ART
In the group with at least 14 days of ART, 5% (99/1930) of deliveries were at less than 34
weeks gestation compared with two and four-fold this rate among the groups with no ART and 1-13 days of ART respectively ( diagnosis and insufficient antenatal ART, and the possibility of shared circumstances leading to the two outcomes, timing of diagnosis was omitted from multivariable models.
In logistic regression analyses, preterm delivery at <34 weeks of gestation was the only factor associated with receipt of 1-13 days of ART (AOR 4.37 vs. delivery ≥34 weeks, 95% CI 1.95- In the model limited to 1473 mother-child pairs with HIV diagnosis before conception, insufficient ART was received in 85 (6%). Absence of a cohabiting partner and IDU history were associated with not receiving antenatal ART (Table 3 ), but these factors were not significantly associated with short duration of ART. Delivery at <34 weeks was associated with short duration of ART only (Table 3) .
Among 596 mother-child pairs with HIV diagnosis after conception, there was insufficient antenatal ART in 86 (14%). History of IDU was associated with not receiving ART but not with short duration of ART (Table 4) . Preterm delivery <34 weeks was associated with both no ART and short duration of treatment.
Vertical transmission
The vertical transmission rate was 1.7% (95% CI 1.1-2.5%) overall and was significantly higher in pregnancies with insufficient ART: 5.8% (95% CI 2.2-12.2%) among pregnancies with no ART and 12.1% (95% CI 3.4-28.2) in those with 1-13 days of ART, compared with 1.1% (95% CI 0.6-1.9) among those with longer duration of ART (p<0.01 for both). Of the 25
HIV-infected infants, 40% (10/25) were born to the 9% of women who received insufficient antenatal ART.
Missing data
Pregnancies with insufficient ART were significantly more likely than those with sufficient ART to have missing data on maternal marital status, HIV disease symptoms and IDU (p<0.02 for each variable), probably because these pregnancies were more likely to be unmonitored or in women with a late HIV diagnosis, and therefore to have less complete antenatal care records.
Discussion
Over the last ten years in this cohort of HIV-infected women giving birth in Western and The women who received insufficient antenatal ART in this cohort were a heterogeneous group.
Factors imposing a time limit on possible duration of antenatal ART (i.e. late antenatal HIV diagnosis and preterm delivery) were associated with not receiving ART and particularly with short duration (1-13 days) of ART. Women who received no antenatal ART were more likely to have characteristics suggesting marginalisation, such as being single and having an IDU history. They were also significantly less likely to have severe symptomatic HIV disease, which may have contributed to a lack of health-seeking behaviour, or perceived lack of need for treatment.
Delivery at <34 weeks gestation was associated with an almost three-fold increased risk of no antenatal ART and over four-fold increased risk of receiving 1-13 days antenatal ART, and was a particularly important risk factor for insufficient ART among women diagnosed antenatally.
Preterm delivery is an important practical barrier to women receiving sufficient antenatal prophylaxis before delivery [4] , is associated with detectable viral load at delivery [28] and is a risk factor for intrapartum MTCT, further raising this risk by precluding elective caesarean section [29, 30] . Antenatal HAART has been shown to be associated with preterm delivery in several studies including the ECS [10, [31] [32] [33] , but initiation of HAART before or early in pregnancy is also associated with a lower MTCT risk than initiation later in pregnancy [14] .
Although evidence on optimal timing of initiation of antenatal ART is lacking, WHO recommendations suggest starting ART for PMTCT as soon as antenatal care allows [34] . This approach is particularly relevant for women most at risk of preterm delivery [4] , given the value of additional weeks of antenatal ART in reducing MTCT risk [2] .
In this study, the proportion of pregnancies without any antenatal ART (6%) was higher than the 2-3% reported previously in Western Europe [6, 7, 15, 19] . The observed improvement in coverage over time coincides with the scale-up of treatment across Europe [14] , improvements in the uptake of screening [35] and an increase in the proportion of HIVinfected pregnant women with known status at conception [6, 15, 19] . African immigrants (two-fifths of the cohort), were no more likely to be diagnosed late or to lack ART, despite potential problems accessing care after immigration. However, late diagnosis was an important factor overall among women lacking ART, suggesting a lack of antenatal care and health literacy -the capacity to understand and act on health information [36] .
In around half of the pregnancies without antenatal ART the mother was aware of her HIV status before pregnancy, similar to findings from the French Perinatal Cohort [27] . Despite previous contact with healthcare services these women did not benefit from PMTCT interventions, indicating an important missed opportunity for prevention. Information on refusal of antenatal ART was not collected in our study, but in the French study, around a third of women not receiving ART had declined treatment [27] . Lack of continuity between antenatal and general HIV care may contribute to delays in women accessing PMTCT interventions;
having a routine healthcare provider has previously been shown to reduce delays in seeking HIV care after a diagnosis [37] . History of IDU and lack of a partner are factors associated with poor social support and treatment delay [38, 39] . Our results highlight the need for practical support and outreach for women at risk of disengaging from ongoing HIV care before a pregnancy occurs, throughout pregnancy and beyond delivery, to optimise the woman's own health as well as uptake of and adherence to PMTCT interventions [27] .
The association between history of IDU and not receiving ART has previously been reported in pregnant [40] and non-pregnant [41, 42] populations, as has the association between IDU and both lack of antenatal care and late HIV diagnosis [40] . Opioid substitution therapy for pregnant IDUs improves compliance with antenatal care [43] and could form an important component of PMTCT care, together with outreach services.
In this study we lacked information on socioeconomic characteristics (including income, employment and housing), which may be associated with access to PMTCT interventions and care. Women with missed opportunities for PMTCT linked to marginalisation may therefore be incompletely characterised. Differences between countries in HIV epidemiology, screening policies and guidelines [5] may limit the generalisability of these results to specific countries.
The association between missing data on variables of interest and receipt of insufficient antenatal ART suggest an underestimate of the size of association between these and the outcome. Our outcome measure of <14 days of ART was designed to capture women most at risk of vertical transmission but did not necessarily capture all at risk women, since there is no precise duration of ART considered sufficient to minimise MTCT risk. Finally, we lacked information on reasons for non-receipt of ART (including woman's refusal and toxicity), and were therefore unable to fully describe the factors leading to lack of treatment.
In conclusion, there remain missed opportunities for PMTCT and for optimising the health of childbearing women with HIV infection in Europe. An emphasis on earlier antenatal HIV diagnosis and earlier initiation of ART will help reduce transmissions resulting from insufficient ART in pregnancy, but additional interventions may be needed for those at risk of disengagement from care. 
